Board Change • May 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 2 highly experienced directors. Independent Director Fred Hassan was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. New Risk • Apr 02
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$8.2m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$8.2m free cash flow). Earnings are forecast to decline by an average of 34% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (35% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$18m net loss in 2 years). Market cap is less than US$100m (US$14.1m market cap). 공시 • Apr 02
Cocrystal Pharma Announces FDA Fast Track Designation For CDI-988 For Norovirus Infection Treatment And Preventive Cocrystal Pharma, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its oral, direct-acting protease inhibitor, CDI-988, the first oral antiviral candidate being developed for treatment and prophylaxis of norovirus infection. FDA Fast Track designation aims to facilitate the development and accelerate the review process for drugs that treat serious conditions and address unmet medical needs. The designation enables early and frequent communication with the FDA throughout the development process, allows for rolling review of a New Drug Application (NDA), and may qualify a product for Priority Review at the time of NDA submission. CDI-988 was designed and developed as an inhibitor of a highly conserved region of noroviruses, coronaviruses, and other 3CL viral proteases. A Phase 1b norovirus challenge study is underway at Emory University School of Medicine to evaluate CDI-988 to both prevent and treat norovirus infection. Norovirus is responsible for an estimated 685 million global cases each year and approximately $60 billion in worldwide economic impact. In the United States alone, the virus is associated with 21 million infections annually, resulting in around 109,000 hospitalizations, 465,000 emergency department visits, and 900 deaths. The estimated annual economic burden in the U.S. exceeds $10.6 billion. In developing nations, norovirus contributes to up to 1,100,000 hospitalizations and 218,000 pediatric deaths each year. Cocrystal’s ongoing Phase 1b randomized, double-blind, placebo-controlled challenge study (NCT07198139) at Emory University School of Medicine will evaluate CDI-988 in up to 40 healthy adults. The primary endpoint is a reduction in the incidence of clinical symptoms, with secondary endpoints assessing viral shedding, disease severity, safety, and pharmacokinetics. Cocrystal is leveraging its structure-based drug discovery platform technology to design next-generation antiviral candidates that precisely target viral replication mechanisms. By binding to highly conserved regions of viral enzymes, the Company’s compounds aim to maintain potency against mutating strains while minimizing off-target effects, offering potentially safer, broad-spectrum antiviral solutions. This approach streamlines candidate identification and optimization, enabling more rapid progression of promising therapies with robust resistance and safety profiles. 공시 • Mar 10
Cocrystal Pharma, Inc Announces First Subjects Dosed in Phase 1B Study Evaluating Cdi-988 for Norovirus Prevention and Treatment Cocrystal Pharma, Inc. announced the first subjects have been dosed in a Phase 1b norovirus challenge study (NCT07198139) to evaluate CDI-988 as both a preventive and treatment for norovirus infections. This cohort is to assess the infectivity rate of the challenge inoculum, GII.2 (Snow Mountain Virus). CDI-988 is a direct-acting, oral antiviral designed to inhibit a highly conserved region of the viral 3CL protease present in all known norovirus strains, including GII.2, GII.4 and recently re-emerging GII.17 variants. It is the first oral antiviral drug candidate developed for norovirus acute gastroenteritis. The Phase 1b randomized, double-blind, placebo-controlled study is being conducted at Emory University School of Medicine and will enroll up to 40 healthy subjects ages 18–49. All participants will be infected with the norovirus GII.2 (Snow Mountain Virus) strain. The first cohort will evaluate the infectivity rate of the challenge inoculum, GII.2 norovirus. Subsequent cohorts will be orally administered CDI-988 or placebo. The primary endpoint is efficacy versus placebo in reducing the incidence of clinical symptoms. Secondary endpoints include reduction of viral shedding and disease severity, and safety and pharmacokinetic profiles. CDI-988 previously demonstrated favorable safety and tolerability in a Phase 1 study across all dose levels, including the highest dose of 1200 mg being administered in the Phase 1b human challenge study. In September 2025 Cocrystal received a Study May Proceed Letter from the FDA and in December 2025 received Institutional Review Board approval from Emory University School of Medicine. Price Target Changed • Feb 22
Price target decreased by 20% to US$6.67 Down from US$8.33, the current price target is an average from 3 analysts. New target price is 561% above last closing price of US$1.01. Stock is down 48% over the past year. The company is forecast to post a net loss per share of US$0.80 next year compared to a net loss per share of US$1.72 last year. 공시 • Feb 20
Cocrystal Pharma's First Oral Norovirus Protease Inhibitor CDI-988 to Be Featured at the International Society for Antiviral Research Conference (ICAR) 2026 Cocrystal Pharma, Inc. announced that initial progress of a norovirus challenge study with its direct-acting, oral antiviral inhibitor CDI-988 will be presented at the 39thInternational Conference on Antiviral Research (ICAR2026), being held April 27-May 1 in Prague, Czech Republic. CDI-988 is the first oral antiviral drug candidate under development for the prevention and treatment of acute norovirus gastroenteritis. This infection spreads rapidly in semi-closed and crowded settings such as hospitals, nursing homes, cruise ships, schools, disaster-relief shelters and military facilities, where close contact makes outbreaks especially difficult to control. Norovirus causes an estimated 200,000 deaths worldwide each year at a societal cost of approximately $60 billion. In the U.S., norovirus is responsible for about 21 million cases of acute gastroenteritis annually, including 109,000 hospitalizations, 465,000 emergency department visits and nearly 900 deaths, with an estimated annual economic burden of $10.6 billion. Recent Insider Transactions • Dec 31
Independent Director recently bought US$63k worth of stock On the 26th of December, Phillip Frost bought around 65k shares on-market at roughly US$0.97 per share. This transaction amounted to 3.8% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$86k more in shares than they have sold in the last 12 months. 공시 • Dec 19
Cocrystal Pharma, Inc. Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus Cocrystal Pharma, Inc. announced the approval from the Institutional Review Board (IRB) at Emory University School of Medicine to initiate a Phase 1b human challenge study with CDI-988. Initial screening of study subjects is currently underway, with enrollment expected to begin in the first quarter of 2026. The IRB approval from Emory University School of Medicine follows Cocrystal's prior regulatory milestones, including U.S. Food and Drug Administration (FDA) clearance of its investigational New Drug (IND) application. CDI-988 is the first oral antiviral drug candidate developed for the prevention and treatment of norovirus acute gastroenteritis. CDI-988 was designed with Cocrystal's proprietary structure-based drug discovery platform technology. In August 2025 Cocrystal announced favorable Phase 1 safety and tolerability data from all CDI-988 dose cohorts including the highest dose of 1200 mg. In September 2025 the Company received a Study May Proceed Letter from the FDA for the Phase 1b challenge study. New Risk • Nov 21
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 35% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 33% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (35% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$17m net loss in 2 years). Market cap is less than US$100m (US$12.7m market cap). 공시 • Oct 30
Cocrystal Pharma, Inc. announced that it has received $1.032803 million in funding Cocrystal Pharma, Inc. announces the completion of a private placement to issue 743,024 shares of its common stock at a price of $1.39 per share for gross proceeds of $1,032,803.36 on October 30, 2025. The four Investors in the private placement are Cocrystal Directors Phillip Frost, M.D., who co-founded the Company and serves as Chairman and CEO of OPKO Health, Inc., Fred Hassan, who is Chairman of the investment firm Caret Group and Director of the private equity firm Warburg Pincus and Richard Pfenniger, and Cocrystal co-CEO and CFO James Martin. Securities are issued pursuant to Regulation D. 공시 • Oct 27
Cocrystal Pharma, Inc. Receives NIH SBIR Award to Advance Its Influenza Inhibitor Program Cocrystal Pharma, Inc. announced it has received a Small Business Innovation Research (SBIR) Phase I award from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID). This approximately $500,000 award will support the Company’s development of a novel, oral, broad-spectrum antiviral candidate for the treatment of influenza A and B infections. Cocrystal plans to utilize these funds to characterize lead candidate molecules that inhibit the target of the essential function of the influenza polymerase complex. The NIH/NIAID Phase I award is designed to assess the scientific, technical and commercial potential of early-stage programs. Successful completion of Phase I may qualify the recipient eligible to apply for a larger Phase II award, which provides additional substantial funding to continue development. The research is supported by the National Institute of Allergy and Infectious Diseases of the NIH under award number 75N93025C00038. The content of this news release is solely the responsibility of Cocrystal and does not necessarily represent the official views of the NIH. New Risk • Sep 16
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 28% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 20% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$17m net loss in 2 years). Shareholders have been diluted in the past year (28% increase in shares outstanding). Market cap is less than US$100m (US$18.6m market cap). 공시 • Sep 16
Cocrystal Pharma, Inc. has completed a Follow-on Equity Offering. Cocrystal Pharma, Inc. has completed a Follow-on Equity Offering.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 2,764,710
Price\Range: $1.7
Discount Per Security: $0.119
Security Name: Warrants
Security Type: Equity Warrant
Securities Offered: 5,529,420
Transaction Features: Registered Direct Offering 공시 • Sep 13
Cocrystal Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $7.25 million. Cocrystal Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $7.25 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 156,270
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 85,834
Transaction Features: At the Market Offering 공시 • Sep 09
Cocrystal Pharma, Inc. Receives Fda Ind Clearance for Challenge Study of Oral Broad-Spectrum Protease Inhibitor Cdi-988, A Potential First Antiviral for Norovirus Prevention and Treatment Cocrystal Pharma, Inc. announced that the Company received a Study May Proceed Letter from the U.S. Food and Drug Administration (FDA) to conduct a Phase 1b challenge study evaluating CDI-988 for the prevention and treatment of norovirus infections. Cocrystal's oral broad-spectrum antiviral candidate CDI-988 represents a potential breakthrough for norovirus - the most common cause of acute viral gastroenteritis. The Phase 1b challenge study is planned to begin before year-end 2025. CDI-988 is a novel pan-viral 3CL protease inhibitor developed for the treatment of norovirus and coronavirus infections. Preclinical data demonstrate that CDI-988 exhibits broad-spectrum antiviral activity by targeting a highly conserved region in the active site of the viral proteases. CDI-988 has shown effectiveness against major norovirus proteases including the prevalent GII.4 and GII.17. Data from the Phase 1 study showed oral CDI-988 to be well tolerated with a favorable safety profile. Currently, there are no approved vaccines or therapeutics for norovirus infections. 공시 • Aug 05
Cocrystal Pharma, Inc. Presents Phase 1 Results for Pan-Viral Inhibitor CDI-988 at Department of Defense Medical Conference Cocrystal Pharma, Inc. announced the presentation of favorable safety and tolerability data from a randomized, double-blinded, placebo-controlled Phase 1 study with its oral, direct-acting pan-viral inhibitor CDI-988 at the 2025 Military Health System Research Symposium (MHSRS), being held August 4-7 in Kissimmee, Florida. The results support Cocrystal's continued clinical development of CDI-988 as a potential norovirus prophylaxis and treatment. In An Oral Pan-viral Protease Inhibitor for the Prevention and Treatment of Norovirus and Coronavirus Infections: Mechanism of Action and Phase 1 Study Results, Sam Lee, Ph.D., Cocrystal President and co-CEO, discussed findings from the CDI-988 Phase 1 single-ascending (SAD) and multiple-ascending (MAD) cohorts. Data indicate that all doses, ranging from 100 mg to 1200 mg, were well tolerated. Overall treatment-emergent adverse events among CDI-988 subjects were 28% (10/36) compared with 40% (4/10) among placebo subjects for the SAD cohorts, and 53% (19/36) and 92% (11/12), respectively, for the MAD cohorts. Headache was the most common adverse event. All subjects in the SAD cohorts and all but one in the MAD cohorts completed the study. No severe treatment-emergent adverse event, no clinically relevant ECG changes and no clinically significant pathology results were reported from the CDI-9 88 Phase 1 single-ascending ("SAD") and multiple-ascending ("MAD) cohorts. "Consistent with interim results from the Phase 1 study, CDI-988 was well-tolerated with a favorable safety profile across all dose levels tested in this study," said Dr. Lee. "Our plan to continue CDI-988's clinical development for norovirus is particularly relevant for the military, where this highly transmissible pathogen purposes significant operational and economic risks. "Norovirus presents significant vaccine development challenges due to its high genetic variability and mutation rate. CDI-988's mechanism of action targeting viral replication and its broad-spectrum coverage offers a promising solution as a potential prophylactic and therapeutic intervention across all norovirus genog Groups including GII.4 and GII.17. This could be a new approach to outbreak prevention and management. The goal of this technology is to facilitate the development of novel broad-spectrum antivirals for the treatment of acute and chronic viral diseases. 공시 • Jul 10
Cocrystal Pharma, Inc. to Present Data from Phase 1 Study of First-In-Class Norovirus Protease Inhibitor CDI-988 at the 9th International Calicivirus Conference Cocrystal Pharma, Inc. announced that its first-in-class pan-viral protease inhibitor CDI-988 has been selected for an oral presentation at the 9th International Calicivirus Conference being held September 7-11, 2025 in Banff, Alberta, Canada. Sam Lee, PhD, the Company's President and co-CEO, will present "Oral Direct-Acting Antiviral CDI-988 for Norovirus Infection Prevention and Treatment: Mechanism of Action and Phase 1 Study Results" on September 11. This helps to identify novel binding sites and allows for a rapid turnaround of structural information through highly automated X-ray data processing and refinement. The goal of this technology is to facilitate the development of best-in-class antiviral therapies that have fast onset of action or shortened treatment time, are safe, well tolerated and easy to administer, and are effective against all viral subtypes that cause disease and have a high barrier to viral resistance. 공시 • Jun 05
Cocrystal Pharma's Novel Norovirus Antiviral to Be Presented at Department of Defense Medical Conference Cocrystal Pharma, Inc. announced that its broad-spectrum protease inhibitor CDI-988 will be featured in an oral presentation at the 2025 Military Health System Research Symposium (MHSRS) being held August 4-7 in Kissimmee, Fla. Cocrystal is developing CDI-988 as a norovirus prophylaxis and treatment. Sam Lee, PhD, the Company's President and co-CEO, will discuss Phase 1 results during the Broad-Spectrum Anti-Viral Countermeasures breakout session on August 4, 2025. This helps to identify novel binding sites and allows for a rapid turnaround of structural information through highly automated X-ray data processing and refinement. The goal of this technology is to facilitate the development of best-in-class antiviral therapies that have fast onset of action or shortened treatment time, are safe, well tolerated and easy to administer; and are effective against all viral subtypes that cause disease and have a high barrier to viral resistance. 공시 • May 29
Cocrystal Pharma, Inc.'S Investigational Drug Candidate Cc-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5n1 Avian Influenza Strain Cocrystal Pharma, Inc. announced that a recent virology study showed its novel, broad-spectrum influenza PB2 inhibitor CC-42344 exhibits strong antiviral activity against the highly pathogenic H5N1 avian influenza A strain (A/Texas/37/2024). On March 25, 2024, the highly pathogenic avian H5N1 influenza virus was confirmed in a dairy cow in Texas and has continued to spread widely in U.S. dairy cattle, causing a few human cases. There is concern that the H5N1 virus could adapt for human-to-human transmission and potentially result in an influenza pandemic. The virology study utilized the highly pathogenic H5 N1 avian strain (influenza A/Texas/37/2024) and was conducted to test antiviral activity of CC-42344 using Tamiflu®? as a reference inhibitor. The data showed that CC-42344 was highly potent against the H5N1 avian virus (EC50, 0.003 uM), approximately 1,000-fold more potent, compared to a refence compound Tamiflu (EC50, 2.69 uM). CC-42344 is currently in development as an oral treatment for pandemic avian and seasonal influenza A infections with initial data showing a favorable safety and tolerability profile. 공시 • Apr 28
Cocrystal Pharma, Inc., Annual General Meeting, Jun 25, 2025 Cocrystal Pharma, Inc., Annual General Meeting, Jun 25, 2025. 공시 • Apr 25
Cocrystal Pharma, Inc.'S Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants Cocrystal Pharma, Inc. announced that its investigative drug candidate CDI-988 was shown to bind to the highly conserved region of the GII.17 protease with excellent potency, similar to that shown across a range of GII.4 norovirus variants that had been the dominant worldwide strains until this year. The high resolution GII.17 protease crystal structures used in determining CDI-988's activity were obtained using the Company's proprietary structure-based platform technology. Cocrystal plans to initiate a human norovirus challenge study in 2025 in the U.S. to evaluate CDI-988 as a potential prevention and treatment of norovirus infection. Norovirus antiviral and vaccine development has been extremely challenging due to high diversity among variants that include 10 genog Groups and 49 genotypes. This helps to identify novel binding sites and allows for a rapid turnaround of structural information through highly automated X-ray data processing and refinement. The goal of this technology is to facilitate the development of best-in-class antiviral therapies that have fast onset of action and/or shortened treatment time, are safe, well tolerated and easy to administer, are effective against all viral subtypes that cause disease and have a high barrier to viral resistance. 공시 • Jan 09
Cocrystal Pharma Reports Phase 1 Results with Oral, Broad-Acting Antiviral Drug Cdi-988 for Prophylaxis and Treatment of Norovirus, Coronaviruses and Other Viral Infections Cocrystal Pharma, Inc. announces favorable safety and tolerability results at dosing up to 800 mg per day for 10 consecutive days from the multiple-ascending dose (MAD) portion of the ongoing Phase 1 study with its oral protease inhibitor CDI-988, the first pan-viral drug candidate in development as an orally administered treatment of norovirus and coronavirus infections. The Company also announces that an additional cohort with a higher dose of 1,200 mg and a shorter treatment duration of five consecutive days will be conducted to further assess CDI-988’s safety, tolerability and pharmacokinetics. CDI-988 is a potent, oral, broad-spectrum antiviral inhibitor of a highly conserved region in the active site of noroviruses, coronaviruses and other 3CL viral proteases. It was specifically designed and developed using Cocrystal’s proprietary structure-based drug discovery platform technology. CDI-988 has shown pan-viral activity against multiple norovirus strains, including the genogroup II, genotype 4 (GII.4) viruses that cause severe vomiting, diarrhea and stomach pain. Human noroviruses are highly contagious, constantly evolving, extremely stable in the environment and associated with debilitating illness. Outbreaks occur most commonly in semi-closed communities such as nursing homes, hospitals, cruise ships, schools, disaster relief sites and military settings. Symptoms include vomiting and diarrhea, with or without nausea and abdominal cramps. Norovirus infection can be much more severe and prolonged in specific risk groups including infants, children, the elderly and people with immunodeficiency.According to the Centers for Disease Control and Prevention (CDC), an estimated 685 million cases and an estimated 200,000 deaths are attributed to norovirus each year worldwide, with an estimated societal cost of approximately $60 billion. In the U.S. alone, noroviruses are responsible for an estimated 21 million cases of acute gastroenteritis annually, including 109,000 hospitalizations, 465,000 emergency department visits and nearly 900 deaths. The estimated annual burden of noroviruses to the U.S. is $10.6 billion, according to the National Institutes of Health (NIH). 공시 • Jan 01
Cocrystal Pharma, Inc. to Extend Phase 2a Influenza Challenge Study with Oral PB2 Inhibitor CC-42344 Cocrystal Pharma, Inc. announced plans to extend enrollment in the Phase 2a human challenge study with its investigational, broad-spectrum, oral influenza PB2 inhibitor CDI-42344 due to unexpectedly low influenza infection among study participants who were challenged with a H3N2 viral strain. This randomized, double-blind, placebo-controlled Phase 2a study is evaluating the safety, tolerability, pharmacokinetics (PK), antiviral activity and clinical measurements of CC-42344 at a single site in the United Kingdom. CC-42344 is a drug candidate in development as an oral treatment for pandemic avian and seasonal influenza A infections. In December 2023, Cocrystal Pharma announced enrollment of the first patient in this study and in May 2024, the Company announced full enrollment of 78 subjects. New Risk • Dec 31
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$17m free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings are forecast to decline by an average of 15% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$26m net loss in 2 years). Market cap is less than US$100m (US$33.1m market cap). New Risk • Nov 15
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$14m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$14m free cash flow). Earnings are forecast to decline by an average of 14% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$26m net loss in 2 years). Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (US$22.4m market cap). Price Target Changed • Oct 04
Price target decreased by 11% to US$8.00 Down from US$9.00, the current price target is an average from 3 analysts. New target price is 338% above last closing price of US$1.83. Stock is down 11% over the past year. The company is forecast to post a net loss per share of US$1.94 next year compared to a net loss per share of US$1.86 last year. 공시 • Jul 18
Cocrystal Pharma, Inc. Reports Favorable Results from Single-Ascending Dose Cohorts of Phase 1 Study with CDI-988, its Oral Pan-Viral Norovirus/Coronavirus Protease Inhibitor Cocrystal Pharma, Inc. reported favorable safety and tolerability results from the single-ascending dose (SAD) cohorts of the Phase 1 study in healthy volunteers with CDI-988, its potent, oral, pan-viral protease inhibitor. CDI-988 was specifically designed and developed using Cocrystal’s proprietary structure-based drug discovery platform technology as a broad-spectrum antiviral inhibitor to a highly conserved region in the active site of 3CL viral proteases. It is being developed as the first dual, broad-spectrum antiviral for the treatment of norovirus and coronaviruses. The single-center, randomized, double-blind Phase 1 study is evaluating the safety, tolerability and pharmacokinetics including a food-effect cohort of orally administered CDI-988 compared with placebo in healthy adults and is being conducted in Australia. Study participants in the SAD cohorts received CDI-988 in doses ranging from 100 mg to 600 mg. All participants completed the study with no discontinuations. There were no serious adverse events or severe treatment-emergent adverse events. No clinically significant observations were noted in laboratory assessments, physical exams or electrocardiograms. 공시 • Jun 20
Cocrystal Pharma Advances Cc-42344 in Influenza A Phase 2A Study, Expects Topline Results by Late 2024 Cocrystal Pharma, Inc. recently completed in vitro studies. CC-42344 is a new class of antiviral drugs designed to block essential steps in the replication and transcription of the influenza A virus. Cocrystal is conducting an influenza A Phase 2a clinical study with orally administered CC-42344 and expects to report topline results in the second half of 2024. This study is evaluating the safety, tolerability, antiviral and clinical benefits in influenza A infected subjects. In late 2022 Cocrystal reported favorable safety and tolerability results from a Phase 1 study in healthy volunteers. Cocrystal demonstrated the potential efficacy of CC-42344 against the new avian flu strain with the recently published genome sequence for H5N1. Using its proprietary structure-based platform, Cocrystal created a high-resolution crystal structure of this avian PB2 protein and confirmed that CC-42344 binds to its highly conserved PB2 region. The in vitro data were generated testing CC-42344 against the avian H5N1 PB2 protein and further support CC-42344’s activity similar to that of Cocrystal’s data with pandemic and seasonal influenza A. Avian influenza A H5N1 was reported in 889 cases and caused 463 deaths in 23 countries between 2003 and April 2024, according to the World Health Organization (WHO). On April 1, 2024, the CDC reported a case of highly pathogenic avian influenza A H5N1 in a farmworker in Texas during a multistate outbreak of avian influenza in dairy cows. Two more cases were subsequently reported in farmworkers in Michigan. The CDC analyzed sera (blood) collected from people of all ages in all 10 Health & Human Services regions during the 2022-2023 and 2021-2022 flu seasons. These samples were challenged with H5N1 virus to see whether there was an antibody reaction. Data from this study suggest that there is extremely low to no population immunity to clade 2.3.4.4b A (H5N1) viruses in the U.S. Antibody levels remained low regardless of whether or not the participants received a seasonal flu vaccination, meaning that seasonal flu vaccination did not produce antibodies to H5N1 viruses. Cocrystal Pharma determined the high resolution X-ray crystal structure of the recent avian influenza A (H5N1) PB2 protein and confirmed activity of CC-42344 in vitro (NIH GeneBank ID:influenza A/Texas/37/2024(H5N1). The crystal structure of the avian influenza A (H5N1) PB2 protein showed new mutations located outside the PB2 active site. Subsequent studies showed that CC-42344 binds to the active site of the avian influenza A (H5N1) PB2 protein as previously demonstrated with the pandemic and seasonal influenza A PB2. Preliminary in vitro assays confirmed that CC-42344 exhibits high potency against the avian influenza A (H5N1) PB2 protein. CC-42344 is Cocrystal’s novel, broad-spectrum, antiviral investigational candidate for the treatment of pandemic and seasonal influenza A. CC-42344 inhibits the first step in influenza A’s viral replication by binding to a highly conserved PB2 site of the influenza polymerase complex that is essential to replication and was discovered using Cocrystal’s proprietary structure-based drug discovery platform technology. Cocrystal is conducting a Phase 2a human challenge study in the United Kingdom to evaluate safety, viral and clinical measures of oral CC-42344 in healthy volunteers who are challenged with influenza A. CC-42344 was advanced into Phase 2a testing following favorable safety and tolerability results reported in a Phase 1 study in healthy volunteers conducted in Australia. In vitro testing showed CC-42344’s excellent antiviral activity against influenza A strains, including pandemic and seasonal strains, as well as against strains resistant to Tamiflu® and Xofluza®, while also demonstrating favorable pharmacokinetic and safety profiles. 공시 • May 01
Cocrystal Pharma, Inc. Announces Completion of Enrollment of 78 Subjects Cocrystal Pharma, Inc. announced completion of enrollment of 78 subjects who were infected with influenza A in a randomized, double-blind, placebo-controlled Phase 2a human challenge clinical study evaluating the safety, tolerability, antiviral and clinical measurements of its novel, broad-spectrum, oral PB2 inhibitor CC-42344. CC-42344 is a new class of antiviral treatment designed to effectively block an essential step in the viral replication andcription of pandemic and seasonal influenza A, and was discovered using the Company's proprietary structure-based drug discovery platform technology. There is an urgent need for new influenza antivirals targeting highly pathogenic avian pandemic and seasonal influenza strains. This human challenge study was conducted in the United Kingdom and was designed to evaluate a favorable safety profile, virological effects, and an improvement in clinical symptom for CC-42344 as a potential oral treatment for pandemic and seasonal influenza A. Cocrystal also plans to begin a Phase 1 study in Australia with an inhaled formulation of CC-42344 as a potentially influenza A treatment and post-exposure prophylaxis. Recent preclinical data showed that inhaled CC-42344 exhibited highly effective delivery into the lung, superior lung exposure, efficacy in influenza-infected human lung epithelia and a favorable safety profile. In December 2023, Cocrystal announced the achievement of first-patient-in for the Phase 2a human challenge clinical trial with CC-42344, an investigational new oral antiviral inhibitor for the treatment of pandemic and seasonal influenzaA. The randomized, double-blind, randomized, double-blind, administered study was designed to evaluate the safety, tolerability, viral and clinical measurements of influenza A infection in subjects dosed with oral CC-42344 treatment. In addition to the health risk, influenza is responsible for approximately $10.4 billion in direct costs for hospitalizations and outpatient visits for adults in the U.S. annually. 공시 • Jan 05
Cocrystal Pharma, Inc. Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investment Candidates Cocrystal Pharma, Inc. provided an update on the clinical development of its oral first-in-class pan-norovirus and pan-coronavirus dual protease inhibitor CDI-988 and its oral PB2 inhibitor CC-42344 for the treatment of pandemic and seasonal influenza A. CDI-988 and CC-42344 were specifically designed and developed using Cocrystal's unique structure-based drug discovery technology platform to be effective on a broad range of viruses causing these diseases. CDI-988 targets a highly conserved region in the active site of the main 3CL protease required for viral RNA replication for pandemic norovirus and coronaviruses, including SARS-CoV-2. CDI-988 is being evaluated for safety and pharmacokinetics in a randomized, double-blinded, placebo-controlled Phase 1 study in healthy subjects being conducted in Australia. The Company reports favorable preliminary data from the single-ascending dose cohorts of the clinical study. Cocrystal expects to report topline results from the Phase 1 study this year. CC-42344 binds to a highly conserved PB2 site of the influenza A polymerase complex and exhibits a novel mechanism of action that inhibits viral replication. A randomized, double-blind, placebo-controlled Phase 2a clinical study with CC-42344 is underway in the United Kingdom. The Company reports favorable tolerability and safety in the first cohort of the Phase 2a influenza A challenge study and expects to report topline Results from the Phase 2a clinical study this year. In 2022 Cocrystal reported favorable safety and tolerability results in the healthy volunteer Phase 1 study with CC-42344 conducted in Australia. Although norovirus is a worldwide public health problem, there are no effective treatments or vaccines. Norovirus afflicts an estimated 685 million people annually at an estimated societal cost of $60 billion. 공시 • Dec 06
Cocrystal Pharma, Inc. Announces First-Patient-In for Phase 2A Human Challenge Study Evaluating Oral Cc-42344 in Pandemic and Seasonal Influenza A Cocrystal Pharma, Inc. announced the achievement of first-patient-in for the Phase 2a human challenge clinical trial with CC-42344, an investigational new oral antiviral inhibitor for the treatment of pandemic and seasonal influenza A. This randomized, double-blind, placebo-controlled study will evaluate the safety, tolerability, viral and clinical measurements of influenza A infection in subjects dosed with oral CC-42344 treatment. 공시 • Nov 30
Cocrystal Pharma, Inc. Highlights Its Novel Inhaled and Oral Influenza A Antiviral Cc-42344 At the World Vaccine Congress West Coast Cocrystal Pharma, Inc. announced the presentation of favorable data demonstrating activity of its potent broad-spectrum PB2 inhibitor CC-42344 against pandemic and seasonal influenza A strains at the World Vaccine Congress West Coast. Cocrystal has initiated a Phase 2a human challenge trial with oral CC-42344 in the UK in subjects infected with influenza A, and plans to begin a Phase 1 trial with inhaled CC-42344 as a potential influenza A treatment and prophylaxis in Australia in the first half of 2024. 공시 • Sep 29
Cocrystal Pharma, Inc. Doses First Subjects in Clinical Study of CDI-988 for Pandemic Norovirus and Coronavirus Cocrystal Pharma, Inc. announced dosing of the first subjects in a Phase 1 clinical trial with its oral, first-in-class pan-norovirus and pan-coronavirus 3CL protease inhibitor CDI-988. This pan-viral protease inhibitor was discovered using the Company's proprietary structure-based drug discovery platform technology. The Phase 1 study will evaluate the safety, tolerability and pharmacokinetics of oral CDI-988 in single ascending doses (SAD) including food effect cohort, and multiple ascending doses (MAD) compared to placebo in healthy volunteers. Recent CDI-988 in vitro studies showed potent broad-spectrum antiviral activity against a panel of pandemic GII.4 norovirus proteases and a favorable pharmacokinetic property targeting the gastrointestinal tract. GII.4 proteases have caused the majority of norovirus outbreaks worldwide since 2002. CDI-988 was specifically designed and developed as a broad-spectrum antiviral inhibitor using Cocrystal's proprietary structure-based Drug discovery platform technology. It targets a highly conserved region in the active site of noroviruses, noroviruses and other 3CL viral proteases. Cocrystal is approved to conduct a CDI-988 Phase 1 study in Australia by that country's Human Research Ethics Committee (HREC). 공시 • Oct 27
Cocrystal Pharma, Inc. Announces Enrollment Completed in Phase 1 Influenza A Study with Cocrystal Pharma's Oral Antiviral Candidate Cc-42344 Cocrystal Pharma, Inc. announced the completion of enrollment in a Phase 1 healthy volunteer study to assess the safety, tolerability and pharmacokinetics (PK) of its orally administered, novel, broad-spectrum antiviral candidate CC-42344 for the treatment of pandemic and seasonalinfluenza A. CC-42344 represents a new class of antiviral treatment designed to block an essential step in the viral replication and transcription of pandemic and seasonal influenza A. In March 2022 enrollment was initiated in the randomized, double-blind, placebo-controlled Phase 1 study, which is being conducted in Australia. In July 2022 the company announced PK results from the single-ascending-dose portion of the study, which support once-daily dosing. Enrollment is now complete with the dose of the multiple-ascending- dose portion of the study. To continue advancing the development of CC-42344, Cocrystal engaged a U.K.-based clinical research organization in August 2022 to conduct a human challenge Phase 2a study evaluating the antiviral activity safety and PK of CC-42344 in subjects infected with influenza A. This study will expose healthy volunteers to the virus in a controlled setting, which will significantly shorten the timeline for generating results. 공시 • Oct 05
Cocrystal Pharma Announces a 1-for-12 Reverse Stock Split Cocrystal Pharma, Inc. announced that its Board of Directors has approved a 1-for-12 reverse stock split of the Company's common stock. The reverse stock split will support maintenance of the Company's Nasdaq Capital Market's listing. On November 16, 2021, Nasdaq Capital Markets LLC notified the Company that the Company was not compliant with Nasdaq Rule 5550(a)(2) by failing to be above $1.00 per share for 30 consecutive trading days. The purpose of the reverse split is to regain compliance with Nasdaq's Rule and avoid delisting of its common stock. Major Estimate Revision • Aug 24
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 losses of -US$0.38 per share expected, vs -US$0.19 per share profit forecast previously. Revenue forecast reaffirmed at US$250.0k. Pharmaceuticals industry in the US expected to see average net income decline 0.5% next year. Consensus price target of US$4.08 unchanged from last update. Share price was steady at US$0.43 over the past week. Major Estimate Revision • Aug 23
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 losses of -US$0.38 per share expected, vs -US$0.19 per share profit forecast previously. Revenue forecast reaffirmed at US$250.0k. Pharmaceuticals industry in the US expected to see average net income decline 0.5% next year. Consensus price target of US$4.08 unchanged from last update. Share price fell 2.5% to US$0.44 over the past week. 공시 • Aug 09
Cocrystal Pharma Engages CRO to Conduct Phase 2a Human Challenge Influenza A Clinical Trial with Novel, Broad-Spectrum Antiviral Candidate CC-42344 Cocrystal Pharma, Inc. announced it has engaged hVIVO, to conduct a Phase 2a clinical trial with the Company’s novel, broad-spectrum, orally administered antiviral candidate CC-42344. This candidate represents a new class of investigational medicine designed to directly inhibit replication of the virus for the treatment of pandemic and seasonal influenza A. The single-center, double-blind, placebo-controlled Phase 2a human challenge trial is designed to evaluate safety, viral and clinical measures of orally administered CC-42344 to subjects challenged with influenza A. The trial is expected to be initiated in the second half of 2023, pending approval from the United Kingdom Medicines and Healthcare Products Regulatory Agency. This study will be conducted at hVIVO’s facility in the United Kingdom. Cocrystal is conducting a Phase 1 study with CC-42344 in healthy subjects in Australia. The Company recently announced pharmacokinetic (PK) data supporting once-daily dosing from the single-ascending dose portion of this study. Enrollment in the multiple-ascending dose portion of the Phase 1 trial is ongoing, with full trial results expected in 2022. 공시 • Jul 15
Cocrystal Pharma, Inc. Reports CC-42344 Pharmacokinetic Data in Influenza A Once-Daily Dosing Cocrystal Pharma, Inc. announced that pharmacokinetic (PK) data from the single ascending dose portion of a Phase 1 study with its novel, broad-spectrum, orally administered antiviral candidate CC-42344 for the treatment of pandemic and seasonal influenza A support the potential for once-daily dosing. The single ascending dose portion of the Phase 1 study has been completed and subjects are currently being enrolled in the multiple ascending dose portion of the Phase 1 study. The randomized, double-controlled, dose-escalating Phase 1 study being conducted in Australia is intended to assess the safety, tolerability and pharmacokinetics of CC-42344 in healthy adults. In March 2022 Cocrystal announced the initiation of study enrollment and in April 2022 the Company announced preliminary Phase 1 data demonstrating a favorable safety and PK profile in the first two cohorts administered single ascending doses of 100 mg and 200 mg. About Cocrystal Pharma, Inc.Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. 공시 • May 20
Nasdaq Grants 180 Days to Cocrystal Pharma to Regain Compliance On May 17, 2022, Cocrystal Pharma, Inc. (the Company") received a letter from the Nasdaq Stock Market LLC (Nasdaq") notifying the Company that the Company is eligible for a second 180 calendar day period, or until November 14, 2022 (the Second Grace Period"), to regain compliance with the Nasdaq Listing Rule 5550(a)(2) (the Rule"). As of the date of the letter, the Company remained noncompliant with the Rule by failing to maintain a minimum bid price for its common stock of at least $1.00 per share for 30 consecutive business days. Prior to the recent letter, the Company had received the original notice of noncompliance with the Rule from Nasdaq wherein the Company had been given until May 16, 2022 to regain compliance. The Company expects to effect a reverse stock split if needed to regain compliance with the Rule prior to the expiration of the Second Grace Period. The letter has no immediate impact on the listing of the Company's common stock, which will continue to be listed and traded on The Nasdaq Capital Market, subject to the Company's compliance with the other continued listing requirements of The Nasdaq Capital Market. Price Target Changed • Apr 27
Price target decreased to US$4.08 Down from US$4.50, the current price target is an average from 2 analysts. New target price is 767% above last closing price of US$0.47. Stock is down 63% over the past year. The company is forecast to post a net loss per share of US$0.15 next year compared to a net loss per share of US$0.16 last year. 공시 • Apr 13
Cocrystal Pharma, Inc. Reports Favorable Preliminary Data from Phase 1 Initial Cohorts with Cc-42344, a Novel, Broad-Spectrum Influenza A Antiviral Cocrystal Pharma, Inc. reported preliminary results of a Phase 1 study with CC-42344, demonstrating a favorable safety and pharmacokinetic profile. CC-42344 is a broad-spectrum oral antiviral for the treatment of pandemic and seasonal influenza A with a novel mechanism of action. The ongoing Phase 1 clinical trial plans to enroll 56 healthy adults. Results from the first two single-ascending dose 100 mg and 200 mg cohorts showed a favorable pharmacokinetic profile of CC-42344. To date, CC-42344, has demonstrated excellent oral bioavailability, dose-dependent plasma exposures, and a half-life supportive of oral daily dosing. The Phase 1 study is designed to evaluate CC-42344 administered in single-ascending and multiple-ascending doses. Cocrystal expects to report full results from the study in 2022. CC-42344 is an oral PB2 inhibitor that blocks an essential step of viral replication and was discovered using Cocrystal’s proprietary structure-based drug discovery platform technology. It is specifically designed to be effective against all significant pandemic and seasonal influenza A strains and to have a high barrier to resistance due to the way the virus’ replication machinery is targeted. CC-42344 targets the influenza polymerase, an essential replication enzyme with several highly essential regions common to multiple influenza strains, including pandemic strains. In vitro testing showed CC-42344’s excellent antiviral activity against influenza A strains, including pandemic and seasonal strains, as well as against strains resistant to Tamiflu® and Xofluza™, while also demonstrating favorable pharmacokinetic and safety profiles. 공시 • Apr 12
Cocrystal Pharma, Inc., Annual General Meeting, May 18, 2022 Cocrystal Pharma, Inc., Annual General Meeting, May 18, 2022, at 14:00 US Eastern Standard Time. Agenda: To Elect five directors for a one-year term expiring at the next annual meeting of stockholders; to Ratify the selection of Weinberg & Company as the Company’s independent registered public accounting firm for the year ending December 31, 2022; to Approve an amendment to Certificate of Incorporation to effect a reverse stock split of our issued and outstanding shares of common stock, par value $0.001 per share, at a ratio to be determined in the discretion of our Board of Directors within a range of one-for-four through one-for-12; and to consider other matters. Price Target Changed • Mar 01
Price target decreased to US$4.08 Down from US$4.50, the current price target is an average from 2 analysts. New target price is 656% above last closing price of US$0.54. Stock is down 66% over the past year. The company is forecast to post a net loss per share of US$0.16 next year compared to a net loss per share of US$0.17 last year. 공시 • Jan 28
Cocrystal Pharma Selects Two Lead Antiviral Drug Candidates for its COVID-19 Oral Drug Program Cocrystal Pharma, Inc. has selected two investigational novel antiviral drug candidates for further development as oral treatments for SARS-CoV-2, the virus that causes COVID-19. CDI-988 and CDI-873 target a highly conserved region in the active site of SARS-CoV-2 main (3CL) protease required for viral RNA replication. Cocrystal plans to initiate a first-in-human trial with one selected candidate as soon as possible this year. Although CDI-988 and CDI-873 are chemically differentiated, both exhibited superior in vitro potency against SARS-CoV-2 with activity maintained against current variants of concern including Omicron. In preclinical studies, both candidates demonstrated a favorable safety profile and pharmacokinetic properties supportive of daily oral dosing. Additionally, CDI-988 and CDI-873 were specifically designed and developed using Cocrystals proprietary structure-based drug discovery platform technology. Cocrystal is focused on rapidly advancing COVID-19 therapeutic candidates with multiple routes of administration. The newly emerging Omicron variant continues to rapidly spread worldwide with breakthrough infection even in people who are fully vaccinated, demonstrating a critical need for effective antiviral therapy for COVID-19. Earlier this month Cocrystal received guidance from the U.S. Food and Drug Administration (FDA) for further development of CDI-45205 in response to the Company’s pre-Investigational New Drug (IND) briefing package. The Company believes the FDAs response clarifies the pathway for a planned Phase 1 study and provides direction for a subsequent Phase 2 study. 공시 • Jan 07
Cocrystal Pharma Receives FDA Guidance to Advance Clinical Development of its COVID-19 Antiviral CDI-45205 Cocrystal Pharma, Inc. announced receipt of guidance from the U.S. Food and Drug Administration (FDA) for the further development of CDI-45205, Cocrystal’s novel SARS-CoV-2 main protease inhibitor as a potential treatment for COVID-19 and its variants via intranasal/pulmonary delivery. The FDA’s guidance was received in a written response to Cocrystal’s pre-Investigational New Drug (IND) briefing package that was submitted in October 2021. The FDA’s response covered topics including preclinical studies, manufacturing, pharmacology and toxicology, and clinical development plans for CDI-45205 for Phase 1 and Phase 2 studies. In preparation for clinical development, Cocrystal intends to conduct CDI-45205 formulation development, IND-enabling studies and virology assessments, as well as API drug manufacturing for use in preclinical and clinical studies. CDI-45205 is one of three COVID-19 programs underway at Cocrystal. In the second COVID-19 program, the Company plans to begin a Phase 1 study also in 2022 with an orally administered main protease inhibitor. In the third COVID-19 program, Cocrystal is using its unique structure-based technology platform to discover replication inhibitors for oral administration. 공시 • Dec 23
Cocrystal Pharma’s Covid-19 Oral and Intranasal/Pulmonary Protease Inhibitors Exhibit Powerful in Vitro Potency Against the Sars-Cov-2 Omicron Variant Cocrystal Pharma, Inc. announced that in vitro studies demonstrate its oral and intranasal/pulmonary SARS-CoV-2 main protease inhibitors exhibit antiviral potency against the Omicron variant. The Company earlier confirmed that its protease inhibitors demonstrated broad-spectrum antiviral activity against SARS-CoV-2 and all major previously identified variants including Delta, Alpha, Beta and Gamma. Cocrystal expects to initiate Phase 1 clinical studies with its COVID-19 intranasal/pulmonary protease inhibitor CDI-45205 and an oral COVID-19 protease inhibitor as rapidly as possible. To confirm the antiviral activity of its protease inhibitors against SARS-CoV-2 Omicron variant, Cocrystal conducted an analysis of SARS-CoV-2 lineages covering all reported Omicron variant sequences including those from South Africa, Europe, Asia and North America, and identified one prevalent mutation in the SARS-CoV-2 main protease. Using its proprietary platform technology and assays, the Company further confirmed in vitro antiviral activity of its protease inhibitors against the Omicron variant. CDI-45205 is one of three COVID-19 programs underway at Cocrystal. In the second COVID-19 program, the Company plans to begin a Phase 1 study also as rapidly as possible with an orally administered protease inhibitor. In the third COVID-19 program, Cocrystal is using its unique structure-based technology platform to discover replication inhibitors for oral administration. CDI-45205 is among a group of protease inhibitors obtained by Cocrystal under an exclusive license agreement with Kansas State University Research Foundation (KSURF) in 2020. CDI-45205 and several analogs showed potent in vitro activity against the SARS-CoV-2 Delta (India/B.1.617.2), Gamma (Brazil/P.1), Alpha (United Kingdom/B.1.1.7) and Beta (South African/B.1.351) variants, surpassing the activity observed with the original Wuhan strain. CDI-45205 has also shown good bioavailability in mouse and rat pharmacokinetic studies via intraperitoneal injection, and no cytotoxicity against a variety of human cell lines. Preclinical research demonstrated a strong synergistic effect with the FDA-approved COVID-19 medicine remdesivir. Additionally, a proof-of-concept animal study demonstrated that daily injection of CDI-45205 exhibited favorable in vivo efficacy in mice infected with MERS-CoV-2. 공시 • Dec 03
Cocrystal Pharma to Discuss Progress with COVID-19 Antiviral Programs and Clinical Strategy During Noble Capital Markets’ Channelchek Virtual Roadshow Cocrystal Pharma, Inc. announced that President and interim CEO Sam Lee, Ph.D. and CFO and interim CEO James Martin will present a company overview in the Noble Capital Markets Virtual Roadshow Series presented by Channelchek. Cocrystal is waiting for response from the FDA on its pre-Investigational New Drug (IND) briefing packaging for CDI-45205, its COVID-19 protease inhibitor for intranasal/pulmonary delivery. The company plans to submit a second briefing package to the FDA, this one for its orally administered COVID-19 protease inhibitor, in the first half of 2022. In a third COVID-19 program, Cocrystal is using its unique structure-based technology platform to discover COVID-19 replication inhibitors for oral administration. Reported Earnings • Nov 17
Third quarter 2021 earnings released: US$0.04 loss per share (vs US$0.046 loss in 3Q 2020) Third quarter 2021 results: Net loss: US$3.94m (loss widened 48% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings. 공시 • Jun 25
Cocrystal Pharma, Inc. Completes IND-enabling Studies with CC-42344 for the Treatment of Seasonal and Pandemic Influenza A, Plans to initiate a Phase 1 Trial in the Third Quarter Cocrystal Pharma, Inc. announced the completion of IND-enabling studies with its potent, broad-spectrum PB2 inhibitor CC-42344 for the treatment of seasonal and pandemic influenza A and plans to initiate Phase 1 clinical development of CC-42344 in the third quarter of 2021. 공시 • Jun 15
CocrystalPharma, Inc ’s Lead COVID-19 Antiviral CDI-45205 Shown to be Active Against SARS-CoV-2 and Two Prominent SARS-CoV-2 Variants CocrystalPharma, Inc. announced that its lead preclinical SARS-CoV-2 3CL protease inhibitor CDI-45205 is active against SARS-CoV-2 and two prominent SARS-CoV-2 variants. A third-party laboratory contracted by Cocrystal conducted in vitro studies evaluating the antiviral activity of CDI-45205 and its analogs in VeroE6-eGFP cells infected with SARS-CoV-2 (Wuhan strain), the United Kingdom variant (B.1.1.7) and the South African variant (B.1.351). CDI-45205 and its analogs showed excellent antiviral activity against both SARS-CoV-2 variants, surpassing the activity observed with SARS-CoV-2 (Wuhan strain). Two reference inhibitors including remdesivir, an FDA-approved SARS-CoV-2 RNA-dependent RNA polymerase inhibitor, and PF-00835231, another SARS-CoV-2 3CL protease inhibitor, were included in the study as comparators. Results showed CDI-45205 had excellent antiviral activity against the United Kingdom variant, with an EC50 of 1.9 uM (remdesivir EC50 0.6 uM; PF-00835231 EC50 >100 uM) and against the South African variant, with an EC50 of 2.5 uM (remdesivir EC50 0.8 uM; PF-00835231 EC50 >100 uM) in the absence of a P-glycoprotein efflux inhibitor. Executive Departure • Jun 08
Co-Founder, Chairman & CEO Gary Wilcox has left the company On the 26th of May, Gary Wilcox was replaced as CEO by Sam Lee after 4.8 years in the role. We don't have any record of a personal shareholding under Gary's name. Gary is the only executive to leave the company over the last 12 months. The current median tenure of the management team is less than a year, which is considered inexperienced in the Simply Wall St Risk Model. Under Gary's leadership, the company delivered a total shareholder return of -92%. Recent Insider Transactions • May 09
Board Member recently sold US$1.7m worth of stock On the 4th of May, Raymond Schinazi sold around 575k shares on-market at roughly US$2.95 per share. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. 공시 • May 04
Cocrystal Pharma, Inc. Provides Update on its COVID-19 Antiviral Discovery and Development Programs Cocrystal Pharma, Inc. announced progress in developing broad-spectrum antiviral drug candidates that target coronaviruses including SARS-CoV-2, the coronavirus that causes COVID-19. the company initiated its COVID-19 program in March 2020 and has since expanded the program with additional development and licensing. Lead candidate CDI-45205: in December 2020 the company announced the selection of CDI-45205 as its lead coronavirus development candidate among a group of protease inhibitors obtained under an exclusive license agreement with Kansas State University Research Foundation (KSURF) announced in 2020. CDI-45205 showed good bioavailability in mouse and rat pharmacokinetic studies via intraperitoneal injection, and also no cytotoxicity against a variety of human cell lines. The company recently demonstrated a strong synergistic effect with the FDA-approved COVID-19 medicine remdesivir. Additionally, a proof-of-concept animal study demonstrated that daily injection of CDI-45205 exhibited favorable in vivo efficacy in MERS-CoV-2 infected mice. The company has obtained promising preliminary pharmacokinetic results and is continuing to further evaluate CDI-45205. Novel SARS-CoV-2 replication inhibitors: the company has leveraged its antiviral development expertise by using its proprietary technology and drug discovery platform to launch a second COVID-19 program with additional antiviral compounds developed. Price Target Changed • Mar 25
Price target decreased to US$4.50 Down from US$5.00, the current price target is an average from 2 analysts. New target price is 224% above last closing price of US$1.39. Stock is up 107% over the past year. Reported Earnings • Mar 19
Full year 2020 earnings released: US$0.17 loss per share (vs US$1.51 loss in FY 2019) Full year 2020 results: Net loss: US$9.65m (loss narrowed 80% from FY 2019). Products in clinical trials Phase II: 1 Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has only fallen by 33% per year, which means it has not declined as severely as earnings. Recent Insider Transactions Derivative • Feb 13
Board Member notifies of intention to sell stock Raymond Schinazi intends to sell 50k shares in the next 90 days after lodging an Intent To Sell Form on the 8th of February. If the sale is conducted around the recent share price of US$2.13, it would amount to US$107k. Since March 2020, Raymond's direct individual holding has decreased from 10.27m shares to 10.13m. There have been no trades via on-market transactions or options from company insiders in the last 12 months. Recent Insider Transactions Derivative • Jan 24
Board Member notifies of intention to sell stock Raymond Schinazi intends to sell roughly 385.64k shares in the next 90 days after lodging an Intent To Sell Form on the 20th of January. If the sale is conducted around the recent share price of US$2.36, it would amount to US$911k. Since March 2020, Raymond's direct individual holding has decreased from 10.27m shares to 10.13m. There have been no trades via on-market transactions or options from company insiders in the last 12 months. 공시 • Jan 22
Cocrystal Pharma Provides Summary of Upcoming Presentation at the Reimagine Health Research Symposium Cocrystal Pharma, Inc. provided the summary of upcoming presentation by Cocrystal President Sam Lee, Ph.D. at the virtual 3rd Annual reimagine Health Research Symposium, University of Arizona College of Medicine. Dr. Lee’s presentation will be available on the Cocrystal website here beginning January 22, 2021. Dr. Lee will provide an overview of the Company’s drug discovery platform technology, including its unique ability to develop broad-spectrum antiviral therapeutics and its advantages compared with the traditional drug discovery and development process. He will emphasize that the technology platform focuses on well-validated antiviral drug targets and review four case studies on the following compounds: CC-31244, a pan-genotypic hepatitis C virus (HCV) non-nucleoside inhibitor that has shown superior activity against all known HCV drug-resistant polymerases, exhibits a high barrier to drug resistance and has successfully completed a Phase 2a clinical trial; Pan-genotypic HCV inhibitors bind to a highly conserved CBP-1 binding pocket of HCV NS3 helicase and inhibit the viral replication; CC-42344, a broad-spectrum pandemic and seasonal influenza A inhibitor that binds to the highly conserved m7GTP binding pocket of PB2, has exhibited a favorable preclinical safety profile and pharmacokinetic properties, and is expected to enter into Phase 1 clinical trials in 2021; and SARS-CoV-2 direct-acting antiviral 3CL (or main) protease inhibitor is in preclinical development for the treatment of COVID-19. 공시 • Jan 20
Cocrystal Pharma Announces Further Development of Influenza A/B Antiviral Compounds by Merck Under Exclusive Worldwide License and Collaboration Agreement Cocrystal Pharma, Inc. announced that it has completed all research obligations under the Merck exclusive worldwide license and collaboration agreement, and that Merck is now solely responsible for further development of the influenza A/B antiviral compounds that were discovered using Cocrystal’s unique structure-based technologies and Nobel Prize-winning expertise. Is New 90 Day High Low • Jan 20
New 90-day high: US$2.19 The company is up 150% from its price of US$0.88 on 21 October 2020. The American market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 11% over the same period. Is New 90 Day High Low • Nov 26
New 90-day high: US$1.71 The company is up 64% from its price of US$1.04 on 27 August 2020. The American market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Reported Earnings • Nov 15
Third quarter 2020 earnings released: US$0.046 loss per share Third quarter 2020 results: Net loss: US$2.67m (loss widened 50% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has fallen by 51% per year, which means it is performing significantly worse than earnings. Is New 90 Day High Low • Oct 28
New 90-day low: US$0.84 The company is down 51% from its price of US$1.73 on 30 July 2020. The American market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. 공시 • Oct 20
Cocrystal Pharma, Inc. Provides Update on Influenza A Program Cocrystal Pharma, Inc. announced promising in vitro and 7-day toxicity data for its influenza A preclinical lead molecule, CC-42344, that is currently being evaluated in IND-enabling studies for the treatment of both seasonal and pandemic influenza strain A. The Company’s fully owned drug candidate CC-42344 is a potent, broad spectrum inhibitor of the influenza replication enzyme targeting the PB2 subunit, and has strong synergistic effects when combined with approved influenza antiviral drugs including Tamiflu (oseltamivir) and Xofluza (baloxavir). The company’s recent data shows that CC-42344 retained single digit nanomolar potency (EC50 = 0.5 nM) against Xofluza (baloxavir) resistant influenza A strain (H1N1, I38T). This can potentially show CC-42344 drug superiority when seeking FDA approval. Additionally, the Company reported a favorable safety profile from the ongoing IND-enabling studies including 7-day rat and dog toxicology studies, genotoxicity, and safety pharmacology. The results show a no adverse effect level of CC-42344 greater than or equal to 1,000 mg/kg in both rat and dog. The Company plans to complete the ongoing IND-enabling studies and enter into clinical trials in 2021. Cocrystal is applying its proprietary platform technology to develop novel, broad spectrum influenza antivirals that are specifically designed to be effective against all significant A strains of the influenza virus and to have a high barrier to resistance due to the mechanism used to target the virus’s replication machinery. CC-42344, the Company’s lead molecule for the treatment of influenza A, binds to a highly conserved PB2 site on the influenza polymerase complex and exhibits a novel mechanism of action that inhibits viral replication. 공시 • Oct 04
United States District Court for the District of New Jersey Enters an Order Preliminarily Approving the Stipulation and Agreement of Settlement with Cocrystal Pharma, Inc On September 22, 2020, United States District Court for the District of New Jersey entered an order preliminarily approving the Stipulation and Agreement of Settlement, dated August 20, 2020 by and among the plaintiffs in the previously disclosed shareholder derivative action and certain related shareholder derivative actions, Cocrystal Pharma, Inc. as the nominal defendant, and defendants, including certain of the company's current and former directors and officers. The settlement as documented in the Stipulation is subject to the approval of the Court. The proposed settlement requires that certain defendants named in the Stipulation, other than the Company, pay the plaintiffs' attorneys' fees and expenses in the amount of $275,000, and that the company adopt within 60 days of the final approval of the settlement by the Court certain corporate governance enhancements described in Exhibit A to the Stipulation. 공시 • Aug 28
Cocrystal Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $15.000001 million. Cocrystal Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $15.000001 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 14,285,715
Price\Range: $1.05
Discount Per Security: $0.0788 공시 • Jul 04
Cocrystal Pharma, Inc.(NasdaqCM:COCP) dropped from Russell Microcap Value Index Cocrystal Pharma, Inc.(NasdaqCM:COCP) dropped from Russell Microcap Value Index 공시 • Jul 02
Cocrystal Pharma, Inc.(NasdaqCM:COCP) dropped from Russell Microcap Index Cocrystal Pharma, Inc.(NasdaqCM:COCP) dropped from Russell Microcap Index 
